GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound I-123 [WO2025097090] | NEO811
Compound class:
Synthetic organic
Comment: NEO-811 is a CRBN-mediated molecular glue degrader of aryl hydrocarbon nuclear translocator (ARNT; HIF-1β). ARNT is the obligate dimerization partner for the HIF-1α and HIF-2α transcriprion factors. Selective ARNT degradation therefore disrupts the expression of hypoxia-inducible genes such as those for cyclin D and VEGF proteins.
The chemical structure for NEO-811 is claimed in patent WO2025097090A1 [1]. |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| NEO-811 was progressed as a clinical candidate for advanced/metastatic clear cell renal cell carcinoma (ccRCC). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT07300241 | Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma | Phase 1 Interventional | Neomorph, Inc | ||